Alnylam Pharmaceuticals Inc (ALNY)

[mlkrborn]

Alnylam Pharma completes ALN-VSP Phase I trial in patients with liver cancer (ALNY) 9.39 : "We are very pleased with the results of our ALN-VSP Phase I trial that demonstrate safety and tolerability of multiple doses of ALN-VSP in addition to evidence for anti-tumor activity and proof of RNAi mechanism from tissue biopsy samples. Indeed, in this very advanced, heavily pre-treated cancer patient population, we have seen multiple patients achieve stable disease and one patient who has achieved a partial response with 70% tumor regression to date and who continues to receive drug after over one full year of treatment."